Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oxabolone cipionate is a synthetic anabolic-androgenic steroid (AAS) and the C17β cypionate ester prodrug of oxabolone (4-hydroxy-19-nortestosterone), itself a derivative of 19-nortestosterone (nandrolone). Upon administration, it is hydrolyzed to release active oxabolone, which binds to androgen receptors in muscle and other tissues. This receptor activation leads to increased protein synthesis and muscle hypertrophy. Oxabolone cipionate was formerly used in Europe for the treatment of osteoporosis but is now considered experimental and no longer produced by pharmaceutical companies. It has been banned as a performance-enhancing drug in sports due to its anabolic effects[1][2][3][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on oxabolone cipionate.